Get Instant Newsletter Alerts to your Mobile Device and Email as soon as the News or Alerts hit the wire.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oralin situtherapeutic treatment for human stem cells. Its goal is to develop and commercialize new treatment options for age-related inflammatory conditions, with hemochromatosis as its initial clinical focus, and to thereafter expand the development of TELOMIR-1 to post-chemotherapy recovery as well as a broader range of other age-related inflammatory diseases and conditions such as osteoarthritis.
| Last: | $1.261 |
|---|---|
| Change Percent: | -1.52% |
| Open: | $1.3 |
| Close: | $1.2805 |
| High: | $1.3 |
| Low: | $1.26 |
| Volume: | 37,570 |
| Last Trade Date Time: | 02/27/2026 12:44:10 pm |
| Market Cap: | $40,225,736 |
|---|---|
| Float: | 20,889,878 |
| Insiders Ownership: | N/A |
| Institutions: | 14 |
| Short Percent: | N/A |
| Industry: | Biotechnology & Life Sciences |
| Sector: | Healthcare |
| Website: | https://www.telomirpharma.com |
| Country: | US |
| City: | Miami |
Get Instant Newsletter Alerts to your Mobile Device and Email as soon as the News or Alerts hit the wire.
**MWN-AI FAQ is based on asking OpenAI questions about Telomir Pharmaceuticals Inc. (NASDAQ: TELO).
Link your X account with Market Wire News to automatically tweet trending stocks news and your portfolio stocks news.
Get instant news alerts to your mobile device as soon as the news hits the wire. Simply add a stock symbol to your portfolio and our service will alert you anytime there is news.
